4HGL

Crystal structure of ck1g3 with compound 1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.282 
  • R-Value Work: 0.260 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Structure-Based Design of Potent and Selective CK1 gamma Inhibitors.

Huang, H.Acquaviva, L.Berry, V.Bregman, H.Chakka, N.O'Connor, A.DiMauro, E.F.Dovey, J.Epstein, O.Grubinska, B.Goldstein, J.Gunaydin, H.Hua, Z.Huang, X.Huang, L.Human, J.Long, A.Newcomb, J.Patel, V.F.Saffran, D.Serafino, R.Schneider, S.Strathdee, C.Tang, J.Turci, S.White, R.Yu, V.Zhao, H.Wilson, C.Martin, M.W.

(2012) ACS Med Chem Lett 3: 1059-1064

  • DOI: 10.1021/ml300278f
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Aberrant activation of the Wnt pathway is believed to drive the development and growth of some cancers. The central role of CK1γ in Wnt signal transduction makes it an attractive target for the treatment of Wnt-pathway dependent cancers. We describe ...

    Aberrant activation of the Wnt pathway is believed to drive the development and growth of some cancers. The central role of CK1γ in Wnt signal transduction makes it an attractive target for the treatment of Wnt-pathway dependent cancers. We describe a structure-based approach that led to the discovery of a series of pyridyl pyrrolopyridinones as potent and selective CK1γ inhibitors. These compounds exhibited good enzyme and cell potency, as well as selectivity against other CK1 isoforms. A single oral dose of compound 13 resulted in significant inhibition of LRP6 phosphorylation in a mouse tumor PD model.


    Organizational Affiliation

    Departments of Medicinal Chemistry; Pharmacokinetics and Drug Metabolism; Oncology Research; and Molecular Structure, Amgen Inc. , 360 Binney Street, Cambridge, Massachusetts 02142, United States.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Casein kinase I isoform gamma-3
A
330Homo sapiensMutation(s): 0 
Gene Names: CSNK1G3
EC: 2.7.11.1
Find proteins for Q9Y6M4 (Homo sapiens)
Go to UniProtKB:  Q9Y6M4
NIH Common Fund Data Resources
PHAROS  Q9Y6M4
Protein Feature View
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
0YO
Query on 0YO

Download CCD File 
A
2-[5-methoxy-2-(quinolin-3-yl)pyrimidin-4-yl]-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
C21 H17 N5 O2
CIUATZJWGJGLPW-UHFFFAOYSA-N
 Ligand Interaction
SO4
Query on SO4

Download CCD File 
A
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
0YOIC50 :  8   nM  PDBBind
0YOIC50:  8   nM  BindingDB
0YOIC50:  3333   nM  BindingDB
0YOIC50:  348   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.282 
  • R-Value Work: 0.260 
  • Space Group: P 31 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 57.439α = 90
b = 57.439β = 90
c = 223.416γ = 120
Software Package:
Software NamePurpose
HKL-2000data collection
AMoREphasing
CNSrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2012-10-08 
  • Released Date: 2012-11-21 
  • Deposition Author(s): Huang, X.

Revision History 

  • Version 1.0: 2012-11-21
    Type: Initial release
  • Version 1.1: 2014-07-02
    Changes: Database references